Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases
COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset o...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455120304014 |
id |
doaj-678afd847ac545cb8ce6cff8ff61f9c1 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jean Bousquet Vincent Le Moing Hubert Blain Wienczyslawa Czarlewski Torsten Zuberbier Rafael de la Torre Nieves Pizarro Lozano Jacques Reynes Anna Bedbrook Jean-Paul Cristol Alvaro A. Cruz Alessandro Fiocchi Tari Haahtela Guido Iaccarino Ludger Klimek Piotr Kuna Erik Melén Joaquim Mullol Boleslaw Samolinski Arunas Valiulis Josep M. Anto |
spellingShingle |
Jean Bousquet Vincent Le Moing Hubert Blain Wienczyslawa Czarlewski Torsten Zuberbier Rafael de la Torre Nieves Pizarro Lozano Jacques Reynes Anna Bedbrook Jean-Paul Cristol Alvaro A. Cruz Alessandro Fiocchi Tari Haahtela Guido Iaccarino Ludger Klimek Piotr Kuna Erik Melén Joaquim Mullol Boleslaw Samolinski Arunas Valiulis Josep M. Anto Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases World Allergy Organization Journal COVID-19 Nrf2 Broccoli Cough challenge TRPA1 TRPV1 |
author_facet |
Jean Bousquet Vincent Le Moing Hubert Blain Wienczyslawa Czarlewski Torsten Zuberbier Rafael de la Torre Nieves Pizarro Lozano Jacques Reynes Anna Bedbrook Jean-Paul Cristol Alvaro A. Cruz Alessandro Fiocchi Tari Haahtela Guido Iaccarino Ludger Klimek Piotr Kuna Erik Melén Joaquim Mullol Boleslaw Samolinski Arunas Valiulis Josep M. Anto |
author_sort |
Jean Bousquet |
title |
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases |
title_short |
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases |
title_full |
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases |
title_fullStr |
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases |
title_full_unstemmed |
Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases |
title_sort |
efficacy of broccoli and glucoraphanin in covid-19: from hypothesis to proof-of-concept with three experimental clinical cases |
publisher |
Elsevier |
series |
World Allergy Organization Journal |
issn |
1939-4551 |
publishDate |
2021-01-01 |
description |
COVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first COVID-19 symptoms. They were found to reduce many of the symptoms rapidly and for a duration of 6–12 h by repeated dosing. When the patient was stable but still suffering from cough and nasal obstruction when not taking the broccoli capsules, a double-blind induced cough challenge confirmed the speed of onset of the capsules (less than 10 min). A second clinical case with lower broccoli doses carried out during the cytokine storm confirmed the clinical benefits already observed. A third clinical case showed similar effects at the onset of symptoms. In the first clinical trial, we used a dose of under 600 μmol per day of glucoraphanin. However, such a high dose may induce pharmacologic effects that require careful examination before the performance of any study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2-interacting nutrients are effective in COVID-19. However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety. |
topic |
COVID-19 Nrf2 Broccoli Cough challenge TRPA1 TRPV1 |
url |
http://www.sciencedirect.com/science/article/pii/S1939455120304014 |
work_keys_str_mv |
AT jeanbousquet efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT vincentlemoing efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT hubertblain efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT wienczyslawaczarlewski efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT torstenzuberbier efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT rafaeldelatorre efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT nievespizarrolozano efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT jacquesreynes efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT annabedbrook efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT jeanpaulcristol efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT alvaroacruz efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT alessandrofiocchi efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT tarihaahtela efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT guidoiaccarino efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT ludgerklimek efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT piotrkuna efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT erikmelen efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT joaquimmullol efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT boleslawsamolinski efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT arunasvaliulis efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases AT josepmanto efficacyofbroccoliandglucoraphaninincovid19fromhypothesistoproofofconceptwiththreeexperimentalclinicalcases |
_version_ |
1724265562837614592 |
spelling |
doaj-678afd847ac545cb8ce6cff8ff61f9c12021-02-17T04:11:36ZengElsevierWorld Allergy Organization Journal1939-45512021-01-01141100498Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical casesJean Bousquet0Vincent Le Moing1Hubert Blain2Wienczyslawa Czarlewski3Torsten Zuberbier4Rafael de la Torre5Nieves Pizarro Lozano6Jacques Reynes7Anna Bedbrook8Jean-Paul Cristol9Alvaro A. Cruz10Alessandro Fiocchi11Tari Haahtela12Guido Iaccarino13Ludger Klimek14Piotr Kuna15Erik Melén16Joaquim Mullol17Boleslaw Samolinski18Arunas Valiulis19Josep M. Anto20Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany; MACVIA France, University Hospital, Montpellier, France; Corresponding author. 273 avenue d’Occitanie, 34090 Montpellier, France.Maladies Infectiouses et Tropicales, CHU Montpellier, FranceDepartment of Geriatrics, Montpellier University Hospital, Montpellier, FranceMedical Consulting Czarlewski, Levallois, France; MASK-air, Montpellier, FranceCharité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, GermanyCIBER Fisiopatologia de La Obesidad y Nutrición (CIBEROBN), Madrid, Spain; IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, SpainIMIM (Hospital del Mar Research Institute), Barcelona, SpainMaladies Infectiouses et Tropicales, CHU Montpellier, FranceMACVIA France, University Hospital, Montpellier, France; MASK-air, Montpellier, FranceLaboratoire de Biochimie et Hormonologie, PhyMedExp, Université de Montpellier, INSERM, CNRS, CHU de Montpellier, FranceFundação ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, BrazilDivision of Allergy, Department of Pediatric Medicine - The Bambino Gesù Children's Research Hospital Holy see, Rome, ItalySkin and Allergy Hospital, Helsinki University Hospital, And University of Helsinki, Helsinki, FinlandDepartment of Advanced Biomedical Sciences, Federico II University, Napoli, ItalyCenter for Rhinology and Allergology, Wiesbaden, GermanyDivision of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, PolandInstitute of Environmental Medicine, Karolinska Institutet and Sachs' Children's Hospital, Stockholm, SwedenRhinology Unit & Smell Clinic, ENT Department, Hospital Clinic - Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, SpainDepartment of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, PolandVilnius University Faculty of Medicine, Institute of Clinical Medicine & Institute of Health Sciences, Vilnius, LithuaniaIMIM (Hospital del Mar Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain; ISGlobal. ISGlobAL, Barcelona, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, SpainCOVID-19 is described in a clinical case involving a patient who proposed the hypothesis that Nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-interacting nutrients may help to prevent severe COVID-19 symptoms. Capsules of broccoli seeds containing glucoraphanin were being taken before the onset of SARS-CoV-2 infection and were continued daily for over a month after the first COVID-19 symptoms. They were found to reduce many of the symptoms rapidly and for a duration of 6–12 h by repeated dosing. When the patient was stable but still suffering from cough and nasal obstruction when not taking the broccoli capsules, a double-blind induced cough challenge confirmed the speed of onset of the capsules (less than 10 min). A second clinical case with lower broccoli doses carried out during the cytokine storm confirmed the clinical benefits already observed. A third clinical case showed similar effects at the onset of symptoms. In the first clinical trial, we used a dose of under 600 μmol per day of glucoraphanin. However, such a high dose may induce pharmacologic effects that require careful examination before the performance of any study. It is likely that the fast onset of action is mediated through the TRPA1 channel. These experimental clinical cases represent a proof-of-concept confirming the hypothesis that Nrf2-interacting nutrients are effective in COVID-19. However, this cannot be used in practice before the availability of further safety data, and confirmation is necessary through proper trials on efficacy and safety.http://www.sciencedirect.com/science/article/pii/S1939455120304014COVID-19Nrf2BroccoliCough challengeTRPA1TRPV1 |